ARCHIVES

Tesetaxel Showed 20 Percent Response In Second-Line Therapy In Phase IIb Trial

This article is from The Cancer Letter archive.

Vol. 35 No. 1 | January 27, 2012

Download PDF Visit The Full Archive

Related Articles

Rituximab Prolonged Survival Of CLL In Phase III Study

September 24, 2010

Eight Probable Minority CCOP Awardees Lister; NCI May Award As Many As 12, With 220 Payline

June 1, 1990

National Policy: IOM Seeks Nominations for Cancer Policy Board

November 29, 1996

NTP Board Okays Three Cooperative Agreement Concepts, Including Corn Oil Carcinogens is Test

October 7, 1983

NIH reauthorization to be topic of July 19 hearing.

July 15, 2005

Funding Opporunities: Program Announcments

January 15, 1999